NCT04738175WITHDRAWNanonymous

A Randomized, Controlled Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19

Sponsor

Source record

Sorrento Therapeutics, Inc.

Phase

Source record

PHASE1

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

COVI-AMG, Placebo

Indication / condition

AI-normalized

Covid19

Intervention

Source record

COVI-AMG, Placebo

Related intelligence directories

Indication directory: Covid19 Modality directory: monoclonal antibody Target directory: COVI-AMG

Source & freshness

Source record

NCT ID

NCT04738175

Original source

ClinicalTrials.gov

Source last updated

Feb 25, 2022

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04738175

Title

A Randomized, Controlled Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19

Sponsor

Sorrento Therapeutics, Inc.

Status

WITHDRAWN

Phase

PHASE1

Condition raw

Covid19

Condition normalized

Covid19

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

COVI-AMG, Placebo

Target normalized

COVI-AMG, Placebo

Interventions

COVI-AMG, Placebo

Public preview

Source record

Subjects will receive a single injection of 40, 100, or 200 mg COVI-AMG or placebo via IV push.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Controlled Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT04738175

Status

WITHDRAWN

Phase

PHASE1

Sponsor

Sorrento Therapeutics, Inc.

Executive brief

Investment-Ready Snapshot

Subjects will receive a single injection of 40, 100, or 200 mg COVI-AMG or placebo via IV push.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedFeb 25, 2022

Internal syncJun 09, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04738175

Indication

Covid19

Modality

monoclonal antibody

Target

COVI-AMG, Placebo

Intervention

COVI-AMG, Placebo

Source record